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Background
Circulatory support is usually not available in developing
countries due to cost restrictions. Long-term devices are
almost always not affordable for our health system and
Thoratec Centrimag® may be an alternative. We report
our experience in the treatment of cardiogenic shock
with this intermediate-term device.
Methods
Thoratec Centrimag® was used in 22 cardiogenic shock
patients. All were INTERMACS class I and all but one
had multiorgan failure. Seventeen (77%) were male, mean
age 41+13 years. Etiology was ischemic in 11(50%),
dilated in 4(22%), and other etiology in 7(32%). Nine
(41%) had previous cardiac arrest with a mean arrest
time of 18+16 min. Circulatory support was biventricular
in 18(82%), univentricular 4(18%), and in 6(27%) an
oxygenator was interposed within the outflow line until
respiratory recovery. Patients with veno-arterial ECMO
configurations were excluded.
Results
Bridge-to-transplant or recovery was obtained in 14 out of
22 (64%). Mean support time 44 days, range 1-292 days.
Eight patients (36%) were supported for more than
4 weeks. Thirty-day post-implant survival was 73%
(16 patients). Post-implant complications were re-explora-
tion for bleeding 7(32%), neurologic dysfunction 3(14%),
pneumonia 8(36%), and renal failure with dialysis in (32%).
Eleven (50%) patients are in NYHA class I after a mean
follow-up time of 32+6 months. Kaplan Meier one-year
survival was 56+11%. Eleven out of 12 (92%) bridged-to-
transplant are in NYHA functional class I with normal
biventricular function. One patient died 3 days post-
transplant due to inflammatory response. Two patients
were bridged-to-recovery. One is in NYHA class I and the
other died due to non-compliance.
Conclusion
Thoratec Centrimag® is useful to provide intermediate-
term circulatory support for cardiogenic shock and mul-
tiorgan failure in a developing country. Support time
longer than 4 weeks is feasible. A multidisciplinary
approach is needed since morbidity is common.
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